SUBSCRIBE
SUBSCRIBE
News   Policy

Hemispherx Biopharma Responding to FDA’s Ampligen Questions

November 3, 2009 | 
1 min read
Bookmark and Share

Philadelphia Business Journal -- Hemispherx Biopharma said Monday its plans to “complete all outstanding queries” from the Food and Drug Administration regarding the company’s new drug application for Ampligen this month and next.
Regulatory
Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Syringe and a vial above the map of the USA. Illustration of the concept of the vaccination and immunization in the United States
Vaccines
FDA Refuses To Review Moderna’s mRNA Flu Vaccine, Claims Trial Inadequacies
February 11, 2026
 · 
4 min read
 · 
Tristan Manalac
Podcast
Weight Loss Drama Compounds on Heels of Novo, Lilly Earnings, Plus Gene Therapy News
February 11, 2026
 · 
1 min read
 · 
Jef Akst
Yellow warning sign symbol or alert safety danger caution illustration icon security message and exclamation triangle information icon on attention traffic background with secure alarm. 3D render.
Regulatory
Hims & Hers’ Woes Compound as FDA Hits Company With Warning Letter
February 10, 2026
 · 
2 min read
 · 
Tristan Manalac
Stagflation, economic slow down or recession while inflation high up, GDP growth decrease causing by unemployment concept, fearful businessman riding fall down economic graph with inflation high up.
Complete response letters
REGENXBIO’s Hunter Syndrome Gene Therapy Fails To Win FDA Nod
February 10, 2026
 · 
2 min read
 · 
Tristan Manalac